gene editing

SynGFN: learning across chemical space with generative flow-based molecular discovery

ChargeNet: E(3) Equivariant Graph Attention Network for Atomic Charge Prediction

Atomic charge is a fundamental quantum chemical property essential for advancing drug design and discovery. Although quantum mechanics (QM) methods offer the highest level of accuracy, their computational demands scale quadratically with the number of atoms, limiting their practicality for large-scale applications. In light of this, empirical and semiempirical methods have been introduced to improve computational efficiency, albeit often at the expense of accuracy. The advent of artificial intelligence has witnessed a growing application of machine learning (ML) techniques to accelerate atomic charge predictions. However, existing ML models often suffer from low accuracy and limited generalization capabilities. To address these challenges, we introduce an advanced equivariant graph attention neural network specifically engineered to model long-range atomic electrostatic interactions with high precision. This model introduces a sophisticated global graph attention mechanism, enabling it to capture charge contributions across multiple scales. By utilizing a combination of structural symmetry-preserving transformations and multiscale attention, our approach not only preserves the inherent symmetries of molecular structures but also substantially improves the model's accuracy, generalization, and robustness in complex scenarios. Our empirical analyses demonstrate that, compared to leading baseline models, the proposed model improves charge prediction accuracy by over 40% on average across various charge-calculation schemes. Remarkably, the model achieves superior performance on the external RESP (restrained electrostatic potential) test data sets, with a 54.6% improvement over the baseline. Additionally, we evaluated our charge model under the setting of virtual screening, where it outperforms both the OPLS3 charges and baseline deep learning models across all evaluation metrics, highlighting its extensive potential for scientific discovery.

PepPCBench is a Comprehensive Benchmarking Framework for Protein-Peptide Complex Structure Prediction

Accurate modeling of protein-peptide interactions is essential for understanding fundamental biological processes and designing peptide-based drugs. However, predicting the complex structures of these interactions remains challenging, primarily due to the high conformational flexibility of peptides. To support a fair and systematic evaluation of recent deep learning (DL) approaches, we introduce PepPCBench, a benchmarking framework tailored to assess protein folding neural networks (PFNNs) in protein-peptide complex prediction. As part of this framework, we curated PepPCSet, a data set of 261 experimentally resolved complexes with peptides ranging from 5 to 30 residues. We benchmark five full-atom PFNNs, including AlphaFold3 (AF3), AlphaFold-Multimer (AFM), Chai-1, HelixFold3 (HF3), and RoseTTAFold-All-Atom (RFAA), using comprehensive evaluation metrics. Our benchmarking reveals meaningful performance differences among these methods and highlights the influence of peptide length, conformational flexibility, and training set similarity on prediction accuracy. While AF3 shows strong performance in structure prediction, further analysis indicates that confidence metrics correlate poorly with experimental binding affinities, underscoring the need for improved scoring strategies and generalizability. By providing a reproducible and extensible framework, PepPCBench enables a robust evaluation of PFNN-based methods and supports their continued development for peptide-protein structure prediction.

One-Shot Rational Design of Covalent Drugs with CovalentLab

Targeted covalent drugs have demonstrated remarkable potential in disease treatment over the past decades. However, existing methods for covalent drug design are often limited to serine and cysteine, ignoring other potentially ligandable binding sites. Statistical analyses indicate that over 95% of binding pockets contain covalent-binding residues, suggesting that all ligands that targeting these pockets possess the potential to be modified into covalent ligands. To achieve this goal, we introduced CovalentLab, an interactive computational platform that integrates ligand-based and warhead-based strategies into a unified workflow for the rational design of covalent ligands. Leveraging a covalent binding site prediction model constructed on ESM-2 with LoRA fine-tuning, CovalentLab enables the prediction and ranking of nine classes of covalent-binding residues in proteins according to their reactivity and facilitates systematic warhead attachment to ligands using 210 electrophilic groups or user-defined warheads. Using this platform, a comprehensive library of more than 100,000 covalent molecules across 95 targets was generated. Notably, CovalentLab has been successfully applied to various essential real-world targets, identifying wet-laboratory-validated bioactive compounds ranging from TRK orthosteric inhibitors to GAC allosteric inhibitors. By bridging gaps in covalent drug discovery, CovalentLab offers a versatile, publicly accessible resource to expand the druggable targets and accelerate the development of targeted covalent therapies.

Effective generation of heavy-atom-free triplet photosensitizers containing multiple intersystem crossing mechanisms based on deep learning

Photodynamic therapy (PDT) is a clinically approved therapeutic modality that has demonstrated significant potential for cancer treatment, and triplet photosensitizers (PSs) play a key role in its efficacy. Despite deep learning having emerged as a next-generation tool for material discovery, existing methods mainly target a limited subset of triplet PSs, such as thermally activated delayed fluorescence (TADF) materials, neglecting the critical intersystem crossing (ISC) between the high-lying singlet and triplet states (ΔESnTn). To overcome this limitation, we compiled a comprehensive dataset (∼1.90 × 109) of triplet PSs encompassing various ISC mechanisms. Then, we proposed a novel strategy that incorporates two models: a fragment-based model (Frag-MD) and a character-based model (MD), both integrating a conditional transformer, recurrent neural networks, and reinforcement learning. In silico experiments revealed that the Frag-MD model outperforms the MD model in generating larger conjugated motifs with higher average ring numbers and atom counts; while the MD model generates twice as many unique motifs and excels in novelty and diversity, as evaluated by conditional and MOSES metrics. Therefore, our approach is highly effective for modifying conjugated motifs and designing novel triplet PSs. Notably, the recently reported high-efficiency triplet PSs have been re-identified through ablation experiments using our proposed models, which target ΔESnTn and significantly outperform traditional baselines, achieving a prediction accuracy of 73% versus 4%. Our approach holds the potential to establish a new paradigm for discovering novel PSs applicable in PDT.

Protein–peptide docking with a rational and accurate diffusion generative model

Improving the predictive performance of binding affinities and poses for protein–cyclic peptide complexes through fine-tuned MM/PBSA(GBSA)-based methods

Abstract Cyclic peptides represent a highly promising class of biopharmaceutical scaffolds. The screening of cyclic peptides against protein targets can be greatly facilitated using computational approaches, especially molecular docking. However, it remains a crucial challenge to accurately predict protein–cyclic peptide (P–cp) interactions employing scoring functions of molecular docking. End-point approaches, such as molecular mechanics generalized Born surface area (MM/GBSA) and molecular mechanics Poisson–Boltzmann surface area (MM/PBSA), provide theoretically more robust frameworks than conventional scoring functions, but their reliability in predicting binding affinities and discriminating native-like binding poses for P–cp complexes remains poorly quantified. Herein, we comprehensively assessed the predictive abilities of MM/PBSA(GBSA) in scoring binding affinities of P–cp complexes and re-ranking their binding poses. The binding affinity scoring ability of MM/PBSA(GBSA) was assessed on a carefully curated dataset consisting of 50 complexes involving P–cp binding affinities, and their re-ranking capability was evaluated on another dataset consisting of the decoys of 81 P–cp complexes. Based on these assessments, we proposed a two-step workflow for predicting P–cp binding affinities. First, we employed the assessed optimal re-ranking method to select the top-1 binding pose; second, we estimated the binding affinity based on the selected top-1 pose using the assessed optimal scoring method. Our proposed workflow, which requires only 3 s for each prediction, achieves binding affinity predictions with a Rp of −0.732 when compared to experimental values, which is twice as high as that of AutoDock CrankPep (Rp = −0.316). This study emphasizes the necessity of using fine-tuned MM/PBSA(GBSA) methods for predicting P–cp interactions.

Revisiting Protein-Protein Docking: A Systematic Evaluation Framework

Protein-protein interactions play pivotal roles in a wide range of biological processes. Determining the atomic-level structures of protein-protein complexes is indispensable for elucidating macromolecular interaction mechanisms and advancing structure-based drug design. Protein-protein docking, as one of the leading computational approaches for predicting complex structures, has seen considerable progress but requires rigorous evaluation in practical applications. In this study, we proposed a comprehensive benchmarking framework to evaluate 11 docking methods spanning traditional (HDOCK, PatchDock, PIPER, ZDOCK) and deep learning (DL)-based (EquiDock, ElliDock, EBMDock, GeoDock, DiffDock-PP, AlphaFold-Multimer, AlphaFold3) approaches. Our framework incorporates the classical DockingBenchmark 5.5 data set for evaluating flexible docking, introduces a newly curated data set (AACBench) for antibody-antigen complex docking, and establishes the PPCBench data set to examine the out-of-distribution (OOD) generalization capabilities of DL-based methods. In docking against apo structures, AlphaFold3 achieves a superior top-5 success rate of 77.98%, whereas the traditional approach HDOCK reaches merely 12.84%, despite its highest top-5 success rate of 85.24% when docking against holo structures. For antibody-antigen docking, AlphaFold3 remains the most accurate method (top-5 success rate: 31.78%) and substantially outperforms AlphaFold-Multimer in modeling the CDR-H3 loop. In OOD generalization tests, all DL-based models exhibit markedly reduced performance on the PPCBench data set. Overall, our work establishes a unified benchmarking framework that enables systematic evaluation of docking methods across diverse tasks and provides critical insights into the strengths and limitations of current docking strategies, thereby informing future developments in protein-protein docking research.

Overcoming Resistance in the Androgen Receptor: Rational and Strategic Design of Advanced Antagonists.

ConspectusProstate cancer (PCa) is the most prevalent malignancy among men worldwide, with its pathogenesis and progression heavily reliant on the sustained activation of the androgen receptor (AR) signaling pathway. The AR, a transcription factor of nuclear receptor superfamily, serves as the most privileged therapeutic target in PCa, as evidenced by the clinical efficacy of first- and second-generation AR antagonists. Current clinically available AR antagonists exclusively target the ligand binding pocket (LBP), suppressing tumor proliferation through competitive inhibition of androgen binding and subsequent blockade of AR signaling transduction. However, their therapeutic utility is invariably limited by acquired resistance mechanisms, including point mutations that alter LBP specificity, AR gene amplification leading to receptor overexpression, and the emergence of constitutively active splice variants that bypass ligand-dependent activation. Thus, the development of novel AR antagonists featuring innovative mechanisms and structural scaffolds is imperative to overcome resistance to antiandrogen therapy. However, the AR exhibits significant structural flexibility, and the lack of antagonist-bound crystal structures has hindered structure-based rational drug design. In this Article, we summarize our advances in elucidating the molecular mechanisms underlying AR conformational regulation and highlight our progress in the structure-based design and development of novel AR antagonists. First, our molecular dynamic (MD) studies collectively elucidate the molecular mechanisms by which the AR ligand binding domain (LBD) regulates its functional states through dynamic conformational changes mediated by distinct allosteric pathways when bound to agonists or antagonists, providing atomic-level insights and structural basis for drug development. Then, we successfully identified structurally diverse lead compounds targeting the LBP through various integrated approaches combining MD simulations, structure-based virtual screening (SBVS), and systematic biological evaluation. These compounds exhibited potent activity against clinically relevant AR mutations F877L, W742C, T878A, and H875Y, demonstrating their potential to overcome mutations-driven resistance. Further, we explored non-LBP mediated strategies for AR antagonism, including: (1) targeting the allosteric binding sites on LBD; (2) identification of novel druggable binding sites; and (3) targeting alternative domains beyond the LBD. As a paradigm-shifting example, we proposed inhibition of AR LBD dimerization as a novel mechanism of action for LBP-targeting AR antagonists. Building upon this insight, we characterized a promising pocket at the dimer interface, designated the Dimerization Interface Pocket (DIP), and developed first-in-class antagonists specifically targeting this site, which exhibit exceptional therapeutic potential. Collectively, these multipronged strategies not only highlight the power of computation-driven approaches in drug discovery but also yield a diverse pipeline of resistance-targeting candidates, directly addressing the unmet clinical need in advanced PCa.

MetalloDock: Decoding Metalloprotein-Ligand Interactions via Physics-Aware Deep Learning for Metalloprotein Drug Discovery.

Accurate prediction of metalloprotein-ligand interactions is critical for metalloprotein-targeted drug discovery. Conventional docking tools and existing deep learning (DL) models fail to reliably capture metal-ligand interactions, hampering the discovery of potent metalloprotein inhibitors. Here, we propose MetalloDock, the first DL-based docking framework specially designed for metalloprotein targets. By innovatively integrating an autoregressive spatial decoding engine with a physics-constrained geometric generation paradigm, MetalloDock can precisely reconstruct metal coordination geometries and accurately capture metal-ligand interactions, which enhance both the accuracy of metalloprotein-ligand docking and binding affinity prediction. Extensive evaluations on our custom-built benchmark data set demonstrate that MetalloDock outperforms existing methods, including AlphaFold3, in docking success rate and virtual screening performance for metalloprotein targets. In real-world applications, MetalloDock successfully identified multiple novel hit compounds in a virtual screening campaign targeting the prostate-specific membrane antigen. Additionally, it enabled rational drug design for acidic polymerase endonuclease, leading to the discovery of potent inhibitors. These results highlight the broad applicability of MetalloDock in accelerating metalloprotein-targeted drug discovery and provide a standardized framework for future evaluation of metalloprotein-specific docking algorithms.

STE-DC2I Uncovers Driver Genes in Colorectal Cancer Subtypes Using Symbolic Trajectory-Embedded Dark Causal Inference

Colorectal cancer (CRC) exhibits substantial molecular heterogeneity, necessitating the inference of subtype-specific driver genes and their interactions for drug-target discovery and precision oncology. Prior studies often fail to capture subtle, latent nonlinear regulatory mechanisms (dark causal relationships) driving tumor progression in specific subtypes. Here, we develop an explainable intelligence computational framework, Symbolic Trajectory-Embedded Dark Causal Interaction Inference (STE-DC2I), which combines symbolic trajectory embedding with historical prediction mechanisms to model nonmonotonic oscillatory dependencies between genes. Integrating single-cell transcriptomic and multiomics profiles from malignant epithelial subpopulations, STE-DC2I classifies CRC subtypes, reconstructs developmental trajectories, and uncovers interpretable subtype-specific driver genes with functional relevance. Unlike correlation-based and explicit causal approaches, STE-DC2I captures weak yet biologically critical regulatory signals, outperforming state-of-the-art methods in predicting subtype-specific CRC driver genes. Functional assays in CRC cell lines (in vitro) validated nine predicted driver genes, highlighting their therapeutic potential.This work systematically explores dark causal interactions between genes in CRC subtypes. STE-DC2I offers interpretable insights and a generalizable strategy for CRC drug-target discovery.

Comprehensive Assessment and Benchmark of Deep Generative Models for Proteolysis TArgeting Chimera (PROTAC) Design